TMPRSS2 and infection: In addition, it has also been shown that SARS‐CoV‐2 uses the transmembrane protease serine 2 (TMPRSS2) for S protein priming (cleavage of the fusion domain) and the inhibition of TMPRSS2 by a clinically approved inhibitor might block further infection.3